Masayuki Taki

843 citations
17 papers · 717 indexed · h-index 13
Topics
Cancer Cells and Metastasis (5 papers)Wnt/β-catenin signaling in development and cancer (3 papers)Mesenchymal stem cell research (2 papers)
Partner nations
JapanBelgiumRussia

In The Last Decade

Masayuki Taki

17 papers receiving 702 citations

Peers

Masayuki Taki
Comparison fields: 5 of 80
  • Molecular Biology 443
  • Oncology 325
  • Cancer Research 131
  • Cell Biology 79
  • Rheumatology 61
Replace Ryoichi Fujimoto with:
Ryoichi Fujimoto Japan
Conway C. Huang United States
Takeshi Ogino Japan
Joji Kato Japan
Kati Räsänen Finland
Emanuela Chiarella Italy
Jong Seok Kang United States
Lenka Kubiczková Czechia
Sonja Levanat Croatia
Andre L. Reed United States
Masayuki Taki relative to Ryoichi Fujimoto Japan Ryoichi Fujimoto's profile →
Citations per field
00.5×1.5×1.8×
Ryoichi Fujimoto · 1×
Citations per year

Countries citing papers authored by Masayuki Taki

Since Specialization
Citations

This map shows the geographic impact of Masayuki Taki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masayuki Taki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masayuki Taki more than expected).

Fields of papers citing papers by Masayuki Taki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masayuki Taki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masayuki Taki. The network helps show where Masayuki Taki may publish in the future.

Co-authorship network of co-authors of Masayuki Taki

This figure shows the co-authorship network connecting the top 25 collaborators of Masayuki Taki. A scholar is included among the top collaborators of Masayuki Taki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masayuki Taki. Masayuki Taki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
#WorkIndexed citations
1 17
2 38
3 22
4 35
5 1
6 76
7 78
8 24
9 17
10 77
11 101
12 164
13 30
14 16
15 2
16 12
17 7

About Masayuki Taki

Masayuki Taki is a scholar working on Oncology, Rheumatology and Genetics, having authored 17 papers that have together received 717 indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (5 papers), Wnt/β-catenin signaling in development and cancer (3 papers) and Mesenchymal stem cell research (2 papers). The work is most often cited by research in Oncology (325 citations), Cancer Research (131 citations) and Molecular Biology (443 citations). Masayuki Taki has collaborated with scholars based in Japan, Belgium and Russia. Frequent co-authors include Nobuyuki Kamata, Masaru Nagayama, Kazuhito Yokoyama, Ryoichi Fujimoto, Satoshi Tsutsumi, Koichiro Higashikawa, Hideo Shigeishi, Kei Tobiume, Shigehiro Ono and Kristin Verschueren. Their work appears in journals such as Cancer Research, International Journal of Cancer and Cancer Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026